Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > halt lift

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Dec 19, 2020 3:04pm

209 Views

Post# 32147513

RE:RE:halt lift

Maui527 wrote: At this point I would rather they wait until Dec 30th, as tax loss selling closes on the 29th. It would take that selling option out of the equation and long term holders would consider riding it out a little longer after the halt is removed, IMO

December 30th would be fine with me ...will it happen? I think not ... I predict a bit later than that ... let's see

<< Previous

Bullboard Posts

Next >>

Crypto and blockchain stock ends year with a profit